Fallopian Tube Cancer
📧 Sign up to get email alerts when something new happens for Fallopian Tube Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-01-07Clinical Trial Update: A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating BAT8006 for platinum-resistant epithelial ovarian cancer, fallopian tube cancer, and primary peritonea…
-
CLINICAL_TRIALS withdrawal · 2025-09-23Clinical Trial Update: REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 [Phase 2, Phase 3]
The REFRaME-O1 trial evaluating Luveltamab Tazevibulin versus investigator's choice chemotherapy for FOLR1-expressing ovarian cancer and rel…
-
CLINICAL_TRIALS withdrawal · 2025-06-03Clinical Trial Update: Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer [Phase 1, Phase 2]
Withdrawal of a Phase 1/2 trial evaluating adding ASTX660 (tolinapant) to paclitaxel with or without bevacizumab in patients with recurrent …
-
CLINICAL_TRIALS withdrawal · 2025-05-23Clinical Trial Update: Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer [Phase 1, Phase 2]
Withdrawal notice for a Phase 1/Phase 2 trial of Niraparib with selenium in BRCA-negative, platinum-resistant fallopian tube, ovarian, and p…
-
CLINICAL_TRIALS withdrawal · 2025-04-06Clinical Trial Update: Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi [Phase 2]
A Phase 2 trial evaluating dostarlimab plus niraparib for relapsed ovarian, fallopian tube, or primary peritoneal cancer has been withdrawn.…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-03-19Clinical Trial Update: A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
Pfizer's post-marketing surveillance study of Zirabev to assess safety and effectiveness in domestic cancer patients has been withdrawn.
-
EMA withdrawal · 2024-10-24EMA Withdrawn: Onbevzi (bevacizumab) — Samsung Bioepis NL B.V.
The EMA has withdrawn the marketing authorization for Onbevzi (bevacizumab) by Samsung Bioepis NL B.V., across multiple cancer indications. …
-
CLINICAL_TRIALS withdrawal · 2021-12-23Clinical Trial Update: DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma [Phase 3]
Phase 3 trial of DCVAC/OvCa with standard of care for relapsed ovarian/fallopian tube/peritoneal cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2020-02-24Clinical Trial Update: Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission [Phase 3]
Phase 3 clinical trial evaluating a vaccine therapy with OPT-821 in ovarian epithelial, fallopian tube, or primary peritoneal cancer was wit…
-
CLINICAL_TRIALS withdrawal · 2019-02-20Clinical Trial Update: Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 1]
Phase 1 trial evaluating metformin hydrochloride with carboplatin and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal…
-
CLINICAL_TRIALS withdrawal · 2018-06-06Clinical Trial Update: PET Imaging of Ovarian Carcinoma With 18F-FSPG [EARLY_Phase 1]
A Phase 1 trial evaluating the PET imaging agent 18F-FSPG for ovarian, fallopian tube, and primary peritoneal cancers has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-05-01Clinical Trial Update: Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 1]
The Phase 1 trial evaluating sirolimus in combination with a vaccine therapy for stage II-IV ovarian, fallopian tube, or primary peritoneal …
-
CLINICAL_TRIALS withdrawal · 2017-02-23Clinical Trial Update: TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer [Phase 3]
Amgen's TRINOVA-3 Phase 3 trial evaluating AMG 386 with paclitaxel and carboplatin for ovarian, fallopian tube, and peritoneal cancers has b…
-
CLINICAL_TRIALS withdrawal · 2016-07-26Clinical Trial Update: Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer [Phase 1]
A Phase 1 trial of talazoparib in combination with the HSP90 inhibitor AT13387 for metastatic advanced solid tumors and recurrent ovarian, f…
-
CLINICAL_TRIALS withdrawal · 2016-04-20Clinical Trial Update: Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]
A Phase 2 trial evaluating letrozole (Femara) versus placebo for ovarian, fallopian tube, or primary peritoneal cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-02-17Clinical Trial Update: Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent [Phase 1]
Phase 1 trial of activated T-cell therapy with low-dose aldesleukin and sargramostim for advanced ovarian, fallopian tube, or primary perito…
-
CLINICAL_TRIALS withdrawal · 2014-12-31Clinical Trial Update: Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy [Phase 3]
A Phase 3 trial of Acetyl-L-Carnitine hydrochloride to prevent chemotherapy-induced peripheral neuropathy in patients with recurrent ovarian…
-
CLINICAL_TRIALS withdrawal · 2014-06-06Clinical Trial Update: A Prospective Trial of COXEN Chemotherapy Prediction [NA]
A prospective trial of COXEN chemotherapy prediction sponsored by the University of Virginia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2013-12-20Clinical Trial Update: Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer [Phase 2]
A Phase 2 safety and efficacy study of gemcitabine plus bevacizumab for platinum-resistant ovarian, fallopian tube, or primary peritoneal ca…
-
CLINICAL_TRIALS withdrawal · 2013-12-18Clinical Trial Update: Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission [Phase 1, Phase 2]
Withdrawal of a Phase 1/2 trial evaluating a cancer vaccine therapy in combination with the IDO1 inhibitor epacadostat (INCB024360) for epit…
-
CLINICAL_TRIALS withdrawal · 2013-06-10Clinical Trial Update: Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin [Phase 2]
A Phase 2 trial of gemcitabine and carboplatin for persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peri…
-
CLINICAL_TRIALS withdrawal · 2012-08-21Clinical Trial Update: Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer [Phase 2]
The Phase 2 trial of olaparib for recurrent BRCA-deficient ovarian cancer has been withdrawn (also related peritoneal and fallopian tube can…